Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56

Benzinga Newsdesk www.benzinga.com Positive 82.0%

Neg 0% Neu 0% Pos 82%

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.